Register Here

Date: Wednesday, July 17

Time: 10PM ET/9PM CT/8PM MT/7PM PT

In this session, basic principles to improving treatment outcomes with canine otitis externa (OE) will be covered. Time will be spent discussing the importance of glucocorticoids, identifying the primary causes for disease and drug selection in the management of canine OE. Additionally, approaches for avoiding common pitfalls will be covered along with strategies to bolster client compliance.

This is a live event only and will not be recorded. 

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

Register Here

Date: Monday, July 22

Time: 7pm ET/6pm CT/5pm MT/4pm PT

Many of you have already experienced STELFONTAⓇ(tigilanol tiglate injection) on your own, while some of you remain curious to try STELFONTA. In this webinar, several of your colleagues will share their individual cases and experience with STELFONTA.

Please join us to learn more about this exciting option for mast cell tumor treatment in dogs!

This is a live event only and will not be recorded.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

STELFONTA is an FDA approved, intratumoral injection indicated for use in dogs for the local treatment of: Non-metastatic cutaneous mast cell tumors anywhere on the body, Non-metastatic subcutaneous mast cell tumors located at or distal to, the elbow or hock

IMPORTANT SAFETY INFORMATION

Accidental self-injection of STELFONTA^® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Some of these cases resulted in amputation. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

Register Here

Date: Wednesday, August 7

Time: 9PM ET/8PM CT/7PM MT/6PM PT

Many of you have already experienced STELFONTAⓇ(tigilanol tiglate injection) on your own, while some of you remain curious to try STELFONTA. In this webinar, several of your colleagues will share their individual cases and experience with STELFONTA.

Please join us to learn more about this exciting option for mast cell tumor treatment in dogs!

This is a live event only and will not be recorded.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

STELFONTA is an FDA approved, intratumoral injection indicated for use in dogs for the local treatment of: Non-metastatic cutaneous mast cell tumors anywhere on the body, Non-metastatic subcutaneous mast cell tumors located at or distal to, the elbow or hock

IMPORTANT SAFETY INFORMATION

Accidental self-injection of STELFONTA^® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Some of these cases resulted in amputation. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

Register Here

Date: Monday, August 12

Time: 7PM ET/6PM CT/5PM MT/4PM PT

In this session, basic principles to improving treatment outcomes with canine otitis externa (OE) will be covered. Time will be spent discussing the importance of glucocorticoids, identifying the primary causes for disease and drug selection in the management of canine OE. Additionally, approaches for avoiding common pitfalls will be covered along with strategies to bolster client compliance.

This is a live event only and will not be recorded. 

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

Register Here

Date: Thursday, September 12

Time: 7PM ET/6PM CT/5PM MT/4PM PT

In this session, basic principles to improving treatment outcomes with canine otitis externa (OE) will be covered. Time will be spent discussing the importance of glucocorticoids, identifying the primary causes for disease and drug selection in the management of canine OE. Additionally, approaches for avoiding common pitfalls will be covered along with strategies to bolster client compliance.

This is a live event only and will not be recorded. 

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

Register Here

Date: Wednesday, September 18

Time: 8PM ET/7PM CT/6PM MT/5PM PT

Many of you have already experienced STELFONTAⓇ(tigilanol tiglate injection) on your own, while some of you remain curious to try STELFONTA. In this webinar, several of your colleagues will share their individual cases and experience with STELFONTA.

Please join us to learn more about this exciting option for mast cell tumor treatment in dogs!

This is a live event only and will not be recorded.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

STELFONTA is an FDA approved, intratumoral injection indicated for use in dogs for the local treatment of: Non-metastatic cutaneous mast cell tumors anywhere on the body, Non-metastatic subcutaneous mast cell tumors located at or distal to, the elbow or hock

IMPORTANT SAFETY INFORMATION

Accidental self-injection of STELFONTA^® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Some of these cases resulted in amputation. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

Register Here

Date: Wednesday, October 9

Time: 7PM ET/6PM CT/5PM MT/4PM PT

Many of you have already experienced STELFONTAⓇ(tigilanol tiglate injection) on your own, while some of you remain curious to try STELFONTA. In this webinar, several of your colleagues will share their individual cases and experience with STELFONTA.

Please join us to learn more about this exciting option for mast cell tumor treatment in dogs!

This is a live event only and will not be recorded.

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.

STELFONTA is an FDA approved, intratumoral injection indicated for use in dogs for the local treatment of: Non-metastatic cutaneous mast cell tumors anywhere on the body, Non-metastatic subcutaneous mast cell tumors located at or distal to, the elbow or hock

IMPORTANT SAFETY INFORMATION

Accidental self-injection of STELFONTA^® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Some of these cases resulted in amputation. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.

Register Here

Date: Wednesday, October 9

Time: 8PM ET/7PM CT/6PM MT/5PM PT

In this session, basic principles to improving treatment outcomes with canine otitis externa (OE) will be covered. Time will be spent discussing the importance of glucocorticoids, identifying the primary causes for disease and drug selection in the management of canine OE. Additionally, approaches for avoiding common pitfalls will be covered along with strategies to bolster client compliance.

This is a live event only and will not be recorded. 

This program has been approved for 1.0 hour of continuing education credit in jurisdictions which recognize RACE approval. Virbac is approved as a NY State sponsor of continuing education for veterinarians and veterinary technicians. You must attend the full presentation to receive CE credit.